About

Providence Therapeutics Providence Therapeutics is a mRNA medicines company developing transformative vaccines for cancer treatment and protection from hard-to-treat infectious diseases. 

Our therapeutics come from a fully integrated, end-to-end Research and Development Ecosystem combining target discovery, our proprietary mRNA platform, our Next Generation Lipids and Lipid Nanoparticle Platform (LNP), and a proven mRNA-LNP manufacturing platform applicable to fully personalized medicine all the way to pandemic scale manufacturing. 

Our Senior Leadership Team and Board of Directors are made up of talented and diverse experts in mRNA science, particularly in areas like immunotherapy, infectious diseases, cancer, and therapeutics. Each member brings a deep understanding and extensive experience, which helps our organization stay ahead in mRNA technology, including drug development and vaccine production.

Good communication and teamwork are key to our success, especially in the fast-changing world of biotechnology. Our team's ability to think ahead and make smart decisions is enhanced by their experience, including involvement in vaccine initiatives and guiding companies through the process of becoming publicly traded. This experience provides us with invaluable insights and strategic planning capabilities.

Providence was founded in 2015 as a cancer-focused RNA drugs company that, by 2020, was months from launching clinical studies for fully personalized ovarian cancer and glioblastoma vaccines. Then, of course, the COVID-19 pandemic hit the World.  

With the correct technology at the right time, Providence pivoted to the development of the PTX-COVID19-B vaccine, which head-to-head, was equivalent to the Pfizer/BioNTech vaccine.

See the results of the vaccine program here.

Due to our successes during the SARS-CoV-2 vaccine program, we have exited the pandemic with a number of exciting partnerships  that have resulted in a robust pipeline in infectious disease vaccines and cancer vaccines